About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 1012 record(s)
Req # A-2022-000123
Adverse Drug Reaction (ADR) for ALFUZOSIN HYDROCHLORIDE. Report number: E2B_05007203.Organization: Health Canada
January 2024
Req # A-2023-000126
Adverse Drug Reactions (ADRs). Report numbers: E2B_00675714, E2B_02977829, E2B_03128456.Organization: Health Canada
January 2024
Req # A-2023-001017
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-107682-242, Deputy Ministerial Meeting with Helium Developers Association of Canada.Organization: Health Canada
January 2024
Req # A-2023-001167
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-109485-722, Deputy Ministerial Meeting with the President and Chief Executive Officer of The Ottawa Hospital.Organization: Health Canada
January 2024
Req # A-2023-000483
A list of every drug approved under Health Canada's Special Access Program (SAP) between January 1, 2018 and July 6, 2023.Organization: Health Canada
January 2024
Req # A-2023-000968
Information on the intended use of a device listed on Medical Device Active License Listing (MDALL). Requesting it for the following: Licence No.: 95942, Type: System, Device class: 2, Device first issue date 2015-10-15, Licence name: VIASURE,…Organization: Health Canada
January 2024
Req # A-2023-00173
My request is in regard to the publication of the 2022 PISA results. I would like to receive the NRBA conducted by Statistics Canada on the non-response rate of schools in Quebec and Alberta and the NRBA conducted by Statistics Canada on the non-…Organization: Statistics Canada
January 2024
Req # A-2023-00044
I would like to know: 1- the number of applications submitted, for the field of dance only, in the following programs: a- Canadian Outreach (Circulation and Touring component) between the dates of December 7, 2022 and April 26, 2023 inclusively, in…Organization: Canada Council for the Arts
December 2023
Req # A-2023-000675
Adverse Drug Reactions (ADRs) for ZOSTAVAX II. Report numbers: E2B_02229369, E2B_02381693, E2B_02396904, E2B_02504551, E2B_01438894, E2B_02504551, E2B_02381693, E2B_02760591, E2B_02511273, E2B_01497636.Organization: Health Canada
December 2023
Req # A-2023-000858
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-106744-816, Upcoming Publication of Proposed and Final Post-Market Decisions for Pesticides.Organization: Health Canada
December 2023